Aromatase Inhibitors
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Aromatase Inhibitors
First-line treatment
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in Clinical Development | ||||
Retrospective Study: Adjuvant Hormone Therapy in LGSC | Two sites | Letrozole, Tamoxifen, Anastrozole | Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival? | Promising PFS and OS in Low Grade Serous Cancer patients treated with letrozole, anastrozole, or tamoxifen following cytoreductive surgery PFS: Not Reached (41 months follow up) Pub 2017 |
Maintenance after first-line therapy: Treatment to prevent relapse after complete or partial response to therapy
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in NCCN Guidelines | ||||
Retrospective Study: Hormonal Maintenance in LGSC | II | Anastrozole, Letrozole, Tamoxifen | Retrospective analysis of Hormonal Maintenance Therapy for Patients With LGS Ovarian Cancer | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation (OBS) in Low Grade Serous OC patients HMT vs OBS: PFS: 64.9 vs 26.4 months* pub 2017 |
Drugs in Clinical Development | ||||
Letrozole University Hospital Basel | Single-site | Letrozole | Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients | Promising activity with minimal toxicity of letrozole maintenance in ER-positive patients Let vs Placebo: All patients: Patients w/o residual disease: Patients w/ residual disease: pub 2018 |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
---|---|---|---|---|
Drugs in Clinical Development | ||||
NCT02283658 | II | Everolimus, Letrozole | A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas | Letrozole+everolimus combination shows promising results in ER-positive ovarian cancer PFS: 3.9 months pub 2017 |
NCT02657928 | II | Letrozole, Ribociclib | A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers. | Letrozole+ribociclib is active in ER+ OC with 25% achieving PFS for 23 weeks or longer, but greatest benefit is seen in LGSOC ORR (HGSOC): 0% abs May 2019 and presentation |
NCT03673124 | II | Letrozole, Ribociclib | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | The combination of letrozole plus ribociclib demonstrates promising activity in women with recurrent LGSOC ORR: 23% abs Mar 2023 and presentation |